Skip to main content

Table 3 Comparison of number of hip fractures (n) during exposed and unexposed person-timea (SIR, 95 % CI)

From: Risk of hip fracture among older people using antihypertensive drugs: a nationwide cohort study

  Total cohort By sex By birth cohort Attributable effect (%)
Exposed person-days (DDD)    Women Men 1935–1944 1925–1934 1915–1924 <1915  
  n SIR (CI) n SIR (CI) n SIR (CI) n SIR (C)I) n SIR (CI) n SIR (CI) n SIR (CI)  
Thiazide 550 0.7 (0.6–0.7) 441 0.7 (0.6–0.8) 109 0.6 (0.5–0.8) 61 0.7 (0.5–0.8) 208 0.6 (0.6–0.7) 258 0.7 (0.6–0.8) 23 0.8 (0.5–1.2) –0.6
Loop diuretic 4752 1.0 (1.0–1.0) 3422 1.0 (0.9–1.0) 1330 1.1 (1.1–1.2) 371 2.0 (1.8–2.3) 1538 1.3 (1.2–1.3) 2543 0.9 (0.8–0.9) 300 0.7 (0.6–0.8) 0.1
Beta blocker 4074 0.7 (0.7–0.8) 3010 0.8 (0.8–0.8) 1064 0.7 (0.6–0.7) 511 0.9 (0.9–1.0) 1700 0.8 (0.8–0.8) 1757 0.7 (0.6–0.7) 106 0.6 (0.5–0.8) –3.5
Calcium channel blocker 5028 0.8 (0.8–0.8) 3736 0.8 (0.8–0.8) 1292 0.7 (0.7–0.8) 642 1.0 (0.9–1.1) 1982 0.8 (0.8–0.8) 2234 0.7 (0.7–0.8) 170 0.7 (0.6–0.8) –3.4
ACE inhibitor 3438 0.9 (0.9–1.0) 2351 1.0 (0.9–1.0) 1087 0.9 (0.8–0.9) 410 1.3 (1.1–1.4) 1389 1.1 (1.0–1.1) 1512 0.8 (0.8–0.8) 127 0.7 (0.6–0.9) –0.6
ACE inhibitor/Thiazide 662 0.7 (0.6–0.7) 520 0.7 (0.6–0.8) 142 0.5 (0.4–0.6) 111 1.9 (0.8–1.2) 264 0.7 (0.6–0.7) 261 0.6 (0.5–0.6) 26 0.9 (0.6–1.3) –0.9
Angiotensin II receptor blocker 2631 0.8 (0.7–0.8) 2041 0.8 (0.8–0.8) 590 0.7 (0.6–0.7) 411 0.9 (0.8–1.0) 1049 0.7 (0.7–0.8) 1094 0.8 (0.7–0.8) 77 0.8 (0.6–1.0) –1.9
Angiotensin II receptor blocker/Thiazide 2122 0.6 (0.6–0.6) 1688 0.6 (0.6–0.7) 434 0.5 (0.4–0.5) 367 0.7 (0.6–0.7) 915 0.6 (0.6–0.6) 790 0.6 (0.5–0.6) 50 0.6 (0.5–0.9) –3.6
  1. SIR Standardized Incidence Ratio, DDD Defined Daily Dose, Attributable effect percentage of hip fractures during DDD exposure throughout the study period
  2. aThe population of Norway born before 1945 and exposed to various antihypertensive drugs in 2005–2010 (exposed person-days, DDD)